Features of the Clinical Course and Prognosis in Patients With Idiopathic Pulmonary
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Idiopathic Pulmonary Arterial Hypertension
- Sponsor
- Russian Cardiology Research and Production Center
- Enrollment
- 150
- Locations
- 1
- Primary Endpoint
- Mortality in 3 years after diagnosed IPAH
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
This study will be performed based on a retrospective analysis of the cases of 150-170 patients with IPAH observed at the Research Institute of Clinical Cardiology over the past 10 years, for a comparative assessment of the survival of groups of patients with IPAH diagnosed in the period 2004-2013 and 2014-2023.
The demographic, clinical, functional, hemodynamic characteristics of patients, comorbidity, blood biomarker levels, received PAH-specific and symptomatic therapy will be assessed in order to determine the clinical characteristics of patients with IPAH.
The prospective part of study will include 50 patients with IPAH.
Investigators
Tamila V. Martynyuk, MD, PhD
Professor, Head of pulmonary hypertension department
Russian Cardiology Research and Production Center
Eligibility Criteria
Inclusion Criteria
- •age over 18 years;
- •verified diagnosis of IPAH
Exclusion Criteria
- •age under 18 years;
- •Other etiology op PAH,
- •ischemic heart disease confirmed by MSCT of the coronary arteries or coronary angiography;
- •diseases of the musculoskeletal system that prevent 6MWT
- •severe liver dysfunction (more than 9 points on the Child-Pugh scale, class C)
- •severe renal dysfunction (CC less than 15 ml/min), need for hemodialysis
Outcomes
Primary Outcomes
Mortality in 3 years after diagnosed IPAH
Time Frame: 3 years